|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In vitro aromatase activity and sensitivity to 4-OHA were measured by determining the conversion of tritiated testosterone to tritiated oestradiol in breast tumour tissue in the absence and presence of 4-OHA (10 nM).
|
7893351 |
1994 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Aromatase is present in human breast tumors and in breast cancer cell lines suggesting the possibility of in-situ estrogen production via the androstenedione to estrone and estradiol pathway.
|
8476772 |
1993 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results indicate that a high proportion of breast tumors have the potential to produce aromatase and KGF, both of which could play important roles in their growth.
|
8499330 |
1993 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The present study sought to provide more direct evidence of the predominant role for stromal cell aromatase in breast tumor tissue.
|
8989259 |
1997 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, RT-PCR analyses of RNA isolated from eight pairs of breast tumor and neighboring normal tissue specimens were performed to evaluate the exon I usage and the distribution of I.3A- and I.3B-containing aromatase RNA messages in breast tumor and neighboring normal tissues.
|
9010331 |
1996 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The analysis revealed that exons I.3 and PII are the two major exons I present in aromatase mRNA isolated from breast tumors, suggesting that promoters I.3 and II are the major promoters driving aromatase expression in breast cancer and surrounding adipose stromal cells (ASCs).
|
9365201 |
1997 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In order to test the hypothesis that tumor aromatase can affect breast tumor growth in a paracrine manner, we have carried out cell culture experiments by co-culturing MCF-7 cells with either MCF-7aro or T-47Daro cells.
|
9449203 |
1998 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Suppression of in situ estrogen biosynthesis can be achieved by the prevention of aromatase expression or by the inhibition of aromatase activity in breast tumors.
|
9696881 |
1998 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, aromatase and/or 5alpha-reductase(s) are expressed in the mammary gland and in a large proportion of human breast tumors.
|
9892013 |
1999 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Transcriptional regulation of CYP19 is complex in breast tissues, in which exon switching in the usage of alternative first exons occurs from predominantly EI.4 in breast tissue from cancer-free women to predominantly EI.3 and PII in breast tumors and quadrants with or without tumor.
|
10690899 |
2000 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Whereas tamoxifen is the endocrine therapy of choice, selective inhibition of aromatase may be equally effective, and possibly less toxic, in the management of patients with hormone-responsive breast tumors.
|
10730684 |
2000 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Basal aromatase activity and the degree of aromatase stimulation by these factors were greater in fibroblasts derived from 'normal' breast tissue than from breast tumours.
|
10731102 |
1999 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cell culture including MCF-7 breast cancer cells, animal experiments using aromatase-transfected breast cancer cells, and transgenic mouse studies have demonstrated that estrogen production in situ plays a more important role than circulating estrogens in breast tumor promotion.
|
10731103 |
1999 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Supporting data for an etiological role of aromatase in breast tumor biology are several-fold.
|
10731105 |
1999 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta.
|
11280806 |
2001 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase activity in extragonadal sites contributes to this source of estrogen and may contribute to breast tumor development and/or growth.
|
11795380 |
2001 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The major promoter usage for aromatase expression in breast tumors (i.e. cAMP-stimulated promoters I.3 and II) is different from that in normal breast tissue (i.e. glucocorticoid-stimulated promoter I.4).
|
11850205 |
2001 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The major promoter usage for aromatase expression in breast tumors (i.e. cAMP-stimulated promoters I.3 and II) is different from that in normal breast tissue (i.e. glucocorticoid-stimulated promoter I.4).
|
11850205 |
2001 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aromatase activity has been demonstrated in breast tissue in vitro, and expression of aromatase is highest in or near breast tumor sites.
|
11897504 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Aromatase activity has been demonstrated in breast tissue in vitro, and expression of aromatase is highest in or near breast tumor sites.
|
11897504 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Aromatase (CYP19) expression in tumor-infiltrating lymphocytes and blood mononuclears.
|
11935306 |
2002 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This hypothesis is sustained by the finding that there is a weak inverse correlation between the expression of COUP-TFI and that of aromatase in breast tumor tissue.
|
11973645 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Increased aromatase expression in breast tumors is attributed to changes in the transcriptional control of aromatase expression.
|
12095949 |
2002 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
|
12114443 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that in postmenopausal women aromatase inhibitors might be considered as an adjuvant approach to the treatment of hormone-dependent breast tumors that overexpress aromatase.
|
12160997 |
2002 |